Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

ISSN： 1745-5057

Source： Women's Health, Vol.5, Iss.2, 2009-03, pp. : 135-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele Vincenzi Bruno Tonini Giuseppe

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence

By Demonty Gaston

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 523-528

Future Medicine

Access to resources Recommend Favorite